![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Conducting Clinical Trial in Patients With Pancreatic Cancer in Dallas
November 15, 2010 09:02 ET
|
Infinity Pharmaceuticals, Inc.
Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer, One of the Most Difficult to Treat Cancers
Spotlight on Pancreatic Cancer Awareness Month in November
DALLAS, Nov. 15,...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Pharmaceuticals to Present at Lazard Healthcare Conference
November 10, 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday,...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Provides Company Update and Reports Third Quarter 2010 Financial Results
November 09, 2010 16:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent business and clinical progress, and announced third quarter 2010 financial...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
November 08, 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced two key appointments to its executive leadership team. The company named Pedro...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Awarded Approximately $750,000 in Grants for Qualifying Therapeutic Development Projects
November 04, 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has been awarded three grants totaling approximately $750,000 under the U.S....
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide
October 26, 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
Encouraging Topline Data From Phase 1 Study of IPI-940 Reported
Decision Demonstrates Strength of Alliance and Underscores Complementary Capabilities of the Partners
CAMBRIDGE, Mass., Oct. 26,...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Announces the Date of Its Third Quarter 2010 Financial Results Conference Call and Webcast
October 25, 2010 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will announce its third quarter 2010 financial results on Tuesday, November 9, 2010 after the financial...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Results Showing Activity of IPI-504 in Patients With Non-Small Cell Lung Cancer Published in Journal of Clinical Oncology
October 14, 2010 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 14, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors
October 10, 2010 06:45 ET
|
Infinity Pharmaceuticals, Inc.
MILAN, Italy, Oct. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small...
![Infinity Pharmaceuticals, Inc. Logo](/news-release/logo/216379/0/216379.jpg?lastModified=12%2F09%2F2016%2022%3A45%3A34&size=2)
Infinity Pharmaceuticals to Present Phase 1 Clinical Data of IPI-926 at ESMO Congress
September 22, 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 22, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented...